Ando Hideya, Matsui Mary S, Ichihashi Masamitsu
Skin Aging and Photo-aging Research Center, Doshisha University, Kizugawa, Kyoto 619-0225, Japan; E-Mail:
Int J Mol Sci. 2010 Jun 18;11(6):2566-75. doi: 10.3390/ijms11062566.
Excess production of melanin or its abnormal distribution, or both, can cause irregular hyperpigmentation of the skin, leading to melasma and age spots. To date, various quasi-drugs that prevent or improve hyperpigmentary disorders have been developed and officially approved by the Ministry of Health, Labor and Welfare of Japan. Many of these inhibit the activity of tyrosinase, an enzyme required for melanin synthesis, for example, by competitive or non-competitive inhibition of its catalytic activity, by inhibiting its maturation, or by accelerating its degradation. In this review, we categorize the quasi-drugs developed in Japan to prevent or treat hyperpigmentary disorders, or both, and discuss perspectives for future development.
黑色素生成过多或其分布异常，或两者兼而有之，可导致皮肤出现不规则色素沉着，引发黄褐斑和老年斑。迄今为止，日本厚生劳动省已研发并正式批准了多种预防或改善色素沉着紊乱的准药品。其中许多药物通过竞争性或非竞争性抑制其催化活性、抑制其成熟或加速其降解等方式，抑制酪氨酸酶（黑色素合成所需的一种酶）的活性。在本综述中，我们对日本研发的用于预防或治疗色素沉着紊乱或两者兼治的准药品进行了分类，并探讨了未来的发展前景。
